Only in Titles

           Search results for: ELISA DICER,DICER1,Endoribonuclease Dicer,Helicase MOI,Helicase with RNase motif,HERNA,Homo sapiens,Human,KIAA0928   

paperclip

#30988100   // Save this To Up

ZC3H12B, a new active member of the ZC3H12 family.

ZC3H12B is the most enigmatic member of the ZC3H12 protein family. The founding member of this family, Regnase-1/MCPIP1/ZC3H12A, is a well-known modulator of inflammation and is involved in the degradation of inflammatory mRNAs. In this study, for the first time, we characterized the properties of the ZC3H12B protein. We show that the biological role of ZC3H12B depends on an intact NYN/PIN RNase domain. Using RNA immunoprecipitation,experiments utilizing actinomycin D and ELISA, we show that ZC3H12B binds endogenous proinflammatory interleukin-6 (IL-6) mRNA in vivo, regulates its turnover and results in reduced production of IL-6 protein upon proinflammattory stimulation with IL 1β. We verified that regulation of IL-6 mRNA stability occurs via interaction of ZC3H12B with the stem-loop structure present in the IL-6 3'UTR. The IL-6 transcript is not the only target of ZC3H12B. ZC3H12B also interacts with other known substrates of Regnase 1 and ZC3H12D, such as the 3'UTRs of IER3 and Regnase-1, and binds IER3 mRNA in vivo. Using immunofluorescence, we examined the localization of ZC3H12B within the cell. The obtained results are consistent with the proposed function of ZC3H12B. ZC3H12B forms small, granule-like structures in the cytoplasm that are characteristic of proteins involved in mRNA turnover control. The overexpression of ZC3H12B inhibits proliferation by stalling the cell cycle in the G2 phase. This effect of ZC3H12B is also NYN/PIN dependent. The analysis of ZC3H12B mRNA level reveals its highest expression in the human brain and the neuroblastoma cell line SH SY5Y although the factors regulating its expression remain elusive. Downregulation of ZC3H12B in SH-SY5Y cells by specific shRNAs results in upregulation of ZC3H12B-target mRNAs.

2655 related Products with: ZC3H12B, a new active member of the ZC3H12 family.

Fibroblast Growth Factor Fibroblast Growth Factor G protein-coupled recepto amyloid beta precursor pr RAP2C, member of RAS onco Yip1 domain family, membe family with sequence simi family with sequence simi cyclin I family, member 2 Primary antibody Caspase Primary antibody Caspase Primary antibody IL-1RAc

Related Pathways

  •  
  • No related Items
paperclip

#30881611   // Save this To Up

Prospective treatment of Parkinson's disease by a siRNA-LDH nanoconjugate.

In the world, among the neurodegenerative diseases, Parkinson's is the second most common disease. Although several medications are available in the market, this disease still remains incurable and only the symptoms are controlled to a certain extent with severe side effects. For these reasons we decided to search for a novel therapeutic measure. The objective of this publication was to find a therapeutic procedure to cure this devastating disease. In this study, a biocompatible, easily permeable, cationic nanoparticle-layered double hydroxide was synthesized. Within the layers of these nanoparticles we intercalated α synuclein siRNA, which helps to silence the α synuclein gene. After the intercalation, which was optimized at a 1 : 40 ratio of siRNA : (LDH), we studied its stability in blood by a RNase protection test and serum protection assay. Both proved that LDH was an excellent nanocarrier that can protect intercalated molecules within its layers. After that, several cellular studies were performed by FACS to evaluate its biocompatibility after intercalation and cellular internalization. Results of the biocompatibility studies found it to be nontoxic and in the cellular internalization study, 51.55% of cells were taken into the nanoconjugate and confocal microscopy supported the data from FACS. Lastly, ELISA was performed to discover protein levels in the control, overexpressed, and treated groups of the SH-SY5Y cell line. These results verified that this nanoconjugate is a protective treatment procedure for Parkinson's disease.

1642 related Products with: Prospective treatment of Parkinson's disease by a siRNA-LDH nanoconjugate.

Antibody to Parkinson Dis Sheep Anti-Human LDH5 Ant G418 Sulfate (siRNA Vecto G418 Sulfate (siRNA Vecto Anti-HBeAg (HBeAb) test s Anti-HBcAg (HBcAb) test s HCV antibody test strip, H. Pylori antibody test s Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA

Related Pathways

  •  
  • No related Items
paperclip

#30776371   // Save this To Up

Ameliorating gut microenvironment through staphylococcal nuclease-mediated intestinal NETs degradation for prevention of type 1 diabetes in NOD mice.

Recent studies have revealed that neutrophil extracellular traps (NETs) provide negative feedback in the progression to chronic inflammation and contribute to the pathogenesis of multiple autoimmune diseases including type 1 diabetes (T1D). In addition, accumulating evidences suggest that gut immunity play a key role in T1D pathogenesis. Our study aimed to evaluate whether staphylococcal nuclease (SNase) targeting intestinal NETs can ameliorate the intestinal inflammatory environment and protect against T1D development in non-obese diabetic(NOD) mice.

1828 related Products with: Ameliorating gut microenvironment through staphylococcal nuclease-mediated intestinal NETs degradation for prevention of type 1 diabetes in NOD mice.

alkaline phosphatase (int (7’-Benzyloxy-indolymet Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA Rabbit Anti-intestinal FA

Related Pathways

paperclip

#30718282   // Save this To Up

The antiviral protein viperin regulates chondrogenic differentiation via CXCL10 protein secretion.

Viperin (also known as radical SAM domain-containing 2 (RSAD2)) is an interferon-inducible and evolutionary conserved protein that participates in the cell's innate immune response against a number of viruses. mRNA is a substrate for endoribonucleolytic cleavage by RNase mitochondrial RNA processing (MRP) and mutations in the RNase MRP small nucleolar RNA (snoRNA) subunit of the RNase MRP complex cause cartilage-hair hypoplasia (CHH), a human developmental condition characterized by metaphyseal chondrodysplasia and severe dwarfism. It is unknown how CHH-pathogenic mutations in RNase MRP snoRNA interfere with skeletal development, and aberrant processing of RNase MRP substrate RNAs is thought to be involved. We hypothesized that viperin plays a role in chondrogenic differentiation. Using immunohistochemistry, real-time quantitative PCR, immunoblotting, ELISA, siRNA-mediated gene silencing, plasmid-mediated gene overexpression, label-free MS proteomics, and promoter reporter bioluminescence assays, we discovered here that viperin is expressed in differentiating chondrocytic cells and regulates their protein secretion and the outcome of chondrogenic differentiation by influencing transforming growth factor β (TGF-β)/SMAD family 2/3 (SMAD2/3) activity via C--C motif chemokine ligand 10 (CXCL10). Of note, we observed disturbances in this viperin-CXCL10-TGF-β/SMAD2/3 axis in CHH chondrocytic cells. Our results indicate that the antiviral protein viperin controls chondrogenic differentiation by influencing secretion of soluble proteins and identify a molecular route that may explain impaired chondrogenic differentiation of cells from individuals with CHH.

1887 related Products with: The antiviral protein viperin regulates chondrogenic differentiation via CXCL10 protein secretion.

HTLV 1 gp21 recombinant p Allergens, Phospholipase anti FAS IgG1 (monoclonal Recombinant Human IP-10 C Recombinant Human PKC the Recombinant Human PKC the Recombinant Human PKC the Viral antibodies, anti-H Rabbit Anti-IEX1 Differen Rabbit Anti-IEX1 Differen Rabbit Anti-IEX1 Differen Rabbit Anti-IEX1 Differen

Related Pathways

  •  
  • No related Items
paperclip

#30630412   // Save this To Up

Treatment of established TH2 cells with 4μ8c, an inhibitor of IRE1α, blocks IL-5 but not IL-4 secretion.

T cell activation induces ER stress and upregulates Inositol Requiring Enzyme 1 alpha (IRE1α), an activator of the unfolded protein response (UPR) pathway. Inhibition of IRE1α RNase activity in activated CD4 splenocytes from naïve mice, via treatment of the cells with the commercially available drug 4μ8c upon activation, results in the reduction of the secretion of proteins IL-5, IL-4, and IL-13. Prior to this work, it was unknown if 4μ8c could inhibit TH2 cytokines in established TH2 cells, cells that are crucial in promoting disease in severe asthma.

2000 related Products with: Treatment of established TH2 cells with 4μ8c, an inhibitor of IRE1α, blocks IL-5 but not IL-4 secretion.

Anti C Reactive Protein A Nrf antioxidant pathway A AZD-4547 Mechanisms: FGFR EnzyChrom™ Kinase Assay Mouse AntiCENPE Target An Hamster AntiSerine Protea anti-C1 inhibitor (4G12), Brain-Specific Angiogenes Brain Specific Angiogenes CRF Anti-Polyvalent HRP EconoTek Alk-Phos Anti-P EconoTek HRP Anti-Polyva

Related Pathways

paperclip

#30473626   // Save this To Up

Role of Leptin/Osteopontin Axis in the Function of Eosinophils in Allergic Rhinitis with Obesity.

Allergic rhinitis (AR) is characterized by tissue and blood eosinophilia. Previous studies showed enhanced eosinophilia in allergic rhinitis patients with obesity, suggesting an association between obesity and eosinophilia. However, the interaction and mechanism between obesity and eosinophilia is still unclear.

2862 related Products with: Role of Leptin/Osteopontin Axis in the Function of Eosinophils in Allergic Rhinitis with Obesity.

Leptin ELISA Kit, Rat Lep Anti beta3 AR Human, Poly Obesity (Human) Antibody Obesity (Human) Antibody Thermal Shaker with cooli Goat Anti-Human Leptin Re FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu

Related Pathways

paperclip

#30377121   // Save this To Up

[Correlation between expressions of myeloperoxidase and eosinophil cationic protein in sputum and clinical features of asthma-chronic obstructive pulmonary disease overlap].

To observe the role of myeloperoxidase(MPO)and eosinophilic cationic protein(ECP)in the airway inflammation and their correlation with clinical feature in asthma-COPD overlap (ACO) patients.

1355 related Products with: [Correlation between expressions of myeloperoxidase and eosinophil cationic protein in sputum and clinical features of asthma-chronic obstructive pulmonary disease overlap].

Anti 3 DG imidazolone Mon Tissue array of gastric d Liver disease spectrum ti Lung disease spectrum tis Colon disease spectrum ti Breast disease spectrum t Rabbit Anti-Rat Androgen Eosinophil Cationic Prote Multiple diseases of live Male genitourinary system Toxoplasma gondii GRA8, r FIV Core Ag, recombinant

Related Pathways

paperclip

#30355343   // Save this To Up

Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation.

The IRE1a-XBP1 pathway is a conserved adaptive mediator of the unfolded protein response. The pathway is indispensable for the development of secretory cells by facilitating protein folding and enhancing secretory capacity. In the immune system, it is known to function in dendritic cells, plasma cells, and eosinophil development and differentiation, while its role in T helper cell is unexplored. Here, we investigated the role of the IRE1a-XBP1 pathway in regulating activation and differentiation of type-2 T helper cell (Th2), a major T helper cell type involved in allergy, asthma, helminth infection, pregnancy, and tumor immunosuppression.

1717 related Products with: Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation.

Epidermal Growth Factor ( Epidermal Growth Factor ( T-cell proliferation grad TCCI T cell proliferation TCCI T cell proliferation T-cell proliferation grad TCBI T cell proliferation TCBI T cell proliferation T-cell proliferation grad TCPI T cell proliferation TCPI T cell proliferation T-cell proliferation grad

Related Pathways

paperclip

#30106152   // Save this To Up

Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway.

The aim of the present study was to evaluate the effects of an estrogen receptor antagonist, fulvestrant, on proliferation and apoptosis of prolactinoma cells, and to reveal potential regulatory mechanisms. Prolactinoma GH3 cells were treated with 10‑6 mol/l fulvestrant for 2, 4, 8, 12 and 24 h. GH3 cell growth was observed under a microscope and cell viability was detected by MTT assay. Morphological changes of the nuclei in GH3 cells were observed by Hoechst 33258 staining and apoptotic rates were detected by flow cytometry. Preprolactin (PPL) and prolactin (PRL) secretion levels from GH3 cells were measured using ELISA. In addition, the protein expression levels of inositol‑requiring enzyme 1 (IRE1), X‑box binding protein (XBP)‑1 and glucose‑regulated protein, 78 kDa (GRP78) in GH3 cells were detected by western blot analysis. Cell density and cell viability of GH3 cells were significantly reduced in a time‑dependent manner following treatment with fulvestrant (P<0.05). GH3 cells treated with fulvestrant also acquired an apoptotic morphology and the apoptotic rate of GH3 cells was significantly increased by fulvestrant in a time‑dependent manner (P<0.05). PPL and PRL secretion levels were significantly reduced by fulvestrant treatment in a time‑dependent manner (P<0.05). The protein expression levels of IRE1, XBP1 and GRP78 were also significantly reduced in a time‑dependent manner following treatment with fulvestrant (P<0.05). Therefore, fulvestrant may inhibit proliferation and promote apoptosis of GH3 cells by downregulating the IRE1/XBP1 signaling pathway.

2624 related Products with: Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway.

Hh Signaling Pathway Anta AP-1 Reporter – HEK293 Wnt Signaling Pathway TCF AZD-3514 Mechanisms: Andr IGF-1R Signaling Phospho- T-Cell Receptor Signaling Estrogen Receptor; Clone Estrogen Receptor; Clone Estrogen Receptor; Clone Epidermal Growth Factor ( Epidermal Growth Factor ( Estrogen Receptor á (Pho

Related Pathways

paperclip

#30092251   // Save this To Up

Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers.

In the present study, a highly effective carrier system has been developed for the delivery of antiviral siRNA mixtures. The developed hybrid microcarriers, made of biodegradable polymers and SiO nanostructures, more efficiently mediate cellular uptake of siRNA than commercially available liposome-based reagents and polyethyleneimine (PEI); they also demonstrate low in vitro toxicity and protection of siRNA from RNase degradation. A series of siRNA designs (targeting the most conserved regions of three influenza A virus (IAV) genes: NP, NS, and PA) were screened in vitro using RT-qPCR, ELISA analysis, and hemagglutination assay. Based on the results of screening, the three most effective siRNAs (PA-1630, NP-717, and NS-777) were selected for in situ encapsulation into hybrid microcarriers. It was revealed that pre-treatment of cells with a mixture of PA-1630, NP-717, and NS-777 siRNAs, delivered by hybrid microcarriers, provided stronger inhibition of viral M1 mRNA expression and control of NP protein level, after viral infection, than single pre-treatment by any of three encapsulated siRNAs used in the study. Moreover, the effective inhibition of replication in several IAV subtypes (H1N1, H1N1pdm, H5N2, and H7N9) using a cocktail of the three selected siRNAs, delivered by our hybrid capsules to the cells, was achieved. In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy.

2707 related Products with: Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers.

HA (Influenza A Virus Hem Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V Rabbit Anti-Hepatitis C V

Related Pathways